Your session is about to expire
← Back to Search
This trial is testing durvalumab with or without lenalidomide to treat patients with cutaneous or peripheral T cell lymphoma that has come back and does not respond to treatment.
- Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified
- Sezary Syndrome
- Mycosis Fungoides
- Cutaneous T-Cell Lymphoma
- Cutaneous T-Cell Non-Hodgkin Lymphoma
- T-Cell and NK-Cell Non-Hodgkin Lymphoma
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
Find a Location
Who is running the clinical trial?
- Your disease has come back after treatment or has not responded to previous treatments.If you have a type of skin cancer called MF that cannot be confirmed through a microscope, the doctor will use specific diagnostic criteria recommended by the International Society of Cutaneous Lymphomas to confirm the diagnosis.You have received and failed to respond to at least two different treatments for your condition. If you have a type of cancer called systemic ALCL, you also must have seen your cancer worsen after receiving brentuximab vedotin treatment.
- Group 1: Arm I (durvalumab)
- Group 2: Arm II (durvalumab, lenalidomide)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the maximum capacity for enrollment in this research project?
"Affirmative. The clinical trial is actively recruiting participants, as noted on the clinicaltrials.gov site. It was initially posted on March 8th 2017 and updated recently on January 28th 2022, seeking 62 individuals from 4 different medical sites."
How many healthcare institutions are conducting this research study?
"This medical experiment is recruiting subjects from M D Anderson Cancer Center, Thomas Jefferson University Hospital, City of Hope Medical Centre and 4 additional sites. Specifically, these are located in Houston (Texas), Philadelphia (Pennsylvania) and Duarte (Californiason Cancer Center, Thomas Jefferson University Hospital, City of Hope Medical Centre and 4 additional sites. Specifically, these are located in Houston (Texas), Philadelphia (Pennsylvania) and Duarte (California)."
What medical indications are typically treated with Lenalidomide?
"Lenalidomide is primarily prescribed to treat chronic lymphocytic leukemia, yet it has also been utilized therapeutically for amyloidosis and muscular dystrophy in individuals who have experienced failure under at least two other systemic chemotherapy treatments."
Are there still open slots for volunteers in this experiment?
"According to the clinicaltrials.gov website, this medical trial is open and recruiting participants since its initial posting on March 8th 2017 and last modification made January 28th 2022."
Has there been any precedent for using Lenalidomide in research?
"Lenalidomide first hit the clinical research scene in 2004, when Saint Joseph Regional Medical Center-Mishawaka conducted an investigation. Over a thousand studies later, there are presently 598 open studies recruiting participants with many of them taking place in Houston, Texas."
Share this study with friends